Safer shield? study tests gentler drug to protect transplant patients from viruses
NCT ID NCT07294547
Summary
This study aims to find out if a drug called valacyclovir works as well as the standard drug, valganciclovir, at preventing dangerous viral infections in people who have received a kidney transplant. Researchers want to see if valacyclovir causes fewer serious side effects, like bone marrow problems. The study will follow 80 transplant patients for two years to compare how well each drug controls the viruses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.